Advancing Our Understanding of ctDNA Dynamics to Guide Drug Development
Time: 10:15 am
day: Day Two
Details:
- Review published and presented data supporting the role of ctDNA in early relapse detection and therapy response prediction.
- Highlight insights gained from >150 MRD studies involving more >50 biopharma collaborators, encompassing a wide range of therapeutic modalities and tumor types
- Discuss how Natera’s extensive real-world database, encompassing >230,000 patients and >800,000 ctDNA timepoints, can be leveraged to analyze diverse and representative patient populations, deepening our understanding of molecular and clinical responses, including the timing, duration, and depth of response
